Skip to main content

Epoch Terminates MGB Eclipse Probe Distribution Deal with Amersham

NEW YORK, Oct. 6 (GenomeWeb News) - Epoch Biosciences said today that it has terminated an arrangement under which its MGB Eclipse genetic analysis probe systems was distributed by Amersham Biosciences.


According to Epoch, the deal was ended because of Amersham's failure to meet contractually established sales goals for the system.  In August, the company disclosed that it anticipated revenues from Amersham would be insignificant for the rest of the year and that its projected revenues for the full-year 2003 would be between $8.5 million and $9.5 million.  Epoch said that this guidance remains unchanged.


Epoch CEO William Gerber said in a statement that the company is in discussions with other potential distribution partners for the MGB Eclipse product line.



The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.